CureVac N.V [NASDAQ: CVAC] disclosed that its COVID-19 vaccine candidate which is known as CVnCoV has passed a first interim analysis at 59 adjudicated COVID-19 cases. The firm revealed that the independent Data Safety Monitoring Board (DSMB) has confirmed that the pivotal Phase 2b/3 study (HERALD) for the first-generation COVID-19 vaccine candidate of CureVac has passed the first analysis.
After the confirmation, DSMB also revealed that now there are no safety concerns linked with the CVnCoV. CureVac has no access to study data. The study will proceed to gather enough data in order to carry out statistically noteworthy efficacy analysis. The HERALD study is carried out in an environment categorized by the spread of multiple virus strains. COVID-19 cases within the study are presently being sequenced to offer perilous corresponding data to the efficacy information.
Furthermore, the study has registered nearly 40,000 volunteers in ten states in Latin America and Europe. Of those volunteers, nearly 75% were registered in Latin America and 25% in Europe. The main aim of the HERALD trial is to highlight the worth of a two-dose inoculation of 12µg of CVnCoV in avoiding COVID-19 infection of any sternness in volunteers without previous contact with SARS-CoV-2.
CureVac has commenced the making of the COVID-19 vaccine candidate in January 2020. The vaccine candidate selected for first clinical expansion, CVnCoV, is an enhanced, non-chemically altered mRNA, encoding the prefusion stabilized full-length spike protein of the SARS-CoV-2 virus, and expressed within Lipid Nanoparticles (LNPs).